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1. Introduction 
The term synergy is derived from the Greek syn-ergos, "working together". Synergies have 
been described in many settings and situations of life, including mechanics, technical 
systems, human social life, and many more. In all cases, synergy describes the fact that a 
system, i.e. the combination and interaction of two or more agents or forces is such that the 
combined effect is greater than the sum of their individual effects. 
This definition implies that there are three possible ways of such an “interaction of agents or 
forces”: these forces could simply add up, not affecting each other (no interaction), their 
combination could produce a greater than expected result (synergy), or the combination 
could lead to a result that is less than the sum of the individual effects. This “negative” 
summation is called antagonism.  
Interactions of biologically active agents are an important aspect of pharmacology and 
biomedicine. In this context, interaction describes the biological activity that results from the 
presence of several drugs at the same time. Such situations occur in numerous clinical 
situations: 
- combinations of cytotoxic drugs in the treatment of cancer and infections require lower 
doses of each drug to obtain better therapeutic effects with less side-effect toxicity. 
- combinations of antibiotics likewise combine better efficiency with fewer side effects 
and reduced development of resistance. 
- many serious clinical situations require administration of several drugs simply because 
of multiple therapeutic indications. Although in such a case drug combinations are not 
formulated to look for synergies, the interactions of these  drugs need to be assessed. 
- the effect of one drug may be augmented by another drug that does not produce such 
an effect on its own 
In all these cases, multiple drugs are administered, and will show some form of interaction, 
synergistic, antagonistic, or none. Methods to determine and quantify drug interactions are 
thus an essential tool in pharmacology. Historically, extracts from plants, animals, or even 
soils were the first classified pharmaceuticals. These were complex mixtures rather than 
single agents, and some ingredients may have interacted with others. Over the years of 
development of pharmacy, isolation, synthesis and marketing of single drugs became the 
accepted standard. Whether a complex mixture or a combination of drugs is used, the 
biological interaction of all active substances should be known. Synergy may be observed in 
simple systems – two drugs that only act on one target protein can show synergism. In such 
a case we can study the interaction of the drugs mechanistically and determine why and 
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how several drugs can reinforce each other (or why they do not). Synergy may also be 
observed in complex settings, such as patients receiving multiple medications. Usually, 
more than one biological target (protein, pathway, or even organ) are involved in such 
cases, and single mechanistic descriptions are not appropriate. Additional parameters to 
consider are drug absorption, tissue distribution, and clearance. It may be expected that 
many drugs interfere with metabolism of other drugs. Thus, a substance B that slows down 
clearance of an active drug A, say by blocking metabolizing enzymes or excretion, may lead 
to a higher effective concentration of A that remains in the body for a longer time. As a 
result, one would notice a greater effect of drug A when given together with B, although the 
two drugs have completely different modes of action. While certainly the combination of 
these two drugs would have a “combined effect is greater than the sum of their individual 
effects”, their combination is synergistic in practical application, but not by the strict 
definition. 
2. Basic models and mechanisms – Synergy on a molecular level 
2.1 A simple reaction scheme for enzyme inhibition 
Drug interaction and synergy has been intensively studied for more than 100 years, and 
some of the numerous concepts will be briefly introduced in this chapter. The simplest 
model cases will be presented, leading to a molecular definition of drug synergy. 
Let us assume a simple enzyme following the laws of mass action and Michaelis-Menten 
kinetics. In the simplest case, this enzyme has an active site, where substrate is being converted 
into product, and possesses one or several specific binding sites for inhibitors (Fig. 1A). A 
competitive inhibitor by definition binds to the active site of the enzyme, displacing the 
substrate. Thus, a mixture of two purely competitive inhibitors will only ever target the active 
site. This is known as mutually exclusive binding. If only the simplest mechanistic case is 
considered, one would not expect a second competitive inhibitor to have any notable effect on 
the first one, other than raising the total amount of inhibitory molecules. 
 
 
Fig. 1. Schematic representation of inhibition mechanisms (A) Competitive inhibition. 
Inhibitor (open circles) binds to the active site of the target protein. The agonist (solid 
circles) binds to the same site. By definition of competitive inhibition, all competitive 
inhibitors bind to the same (active) site. Thus, binding of two competitive inhibitors must be 
mutually exclusive, and they cannot act synergistically on the same target protein. (B) Non-
competitive inhibition. Inhibitor (open squares) binds to a site different from the active site 
of the target molecule. In pure non-competitive inhibition agonist binding is not affected by 
the inhibitor. Inhibition is due to conversion of the target protein into an inactive state. 
A 
B 
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In case of non-competitive inhibition, the inhibitor binds to a location on the enzyme 
different from the active site. Assuming that bound inhibitor converts the enzyme into an 
inactive (non product-forming) state, presence of a non-competitive inhibitor simply 
lowers the amount of active enzyme molecules (Fig. 1B). There are states, where both 
substrate and inhibitor are bound to the enzyme. The effect of several non-competitive 
inhibitors applied together raises the question if synergy can be observed in such a simple 
system. If two non-competitive inhibitors bind to the same site on their target enzyme, 
this inhibitory site can either be occupied by inhibitor A or B, but not by both inhibitors at 
the same time (Fig. 2). This would be a case of mutually exclusive binding of two 
inhibitors. If one inhibitor is present, and the second one added, one may observe indeed 
a greater extend of inhibition, but this would only be due to larger amounts of inhibitory 
molecules being present. At all times, we could predict the total amount of inhibition by 
summations. In the simplest molecular case, two inhibitors targeting the same site would 
produce an additive effect only.  
 
 
Fig. 2. Reaction scheme for two non-competitive inhibitors targeting the same site. Two non-
competitive inhibitors (squares) bind to the same site on the target protein. In this case their 
binding is mutually exclusive. Presence of the second inhibitor increases the total amount of 
inhibitor causing in increased inhibitory effect. This increase is only due to simple 
additivity, and not synergy. 
If, however, two different binding sites for non-competitive inhibitors exist on an enzyme, 
two inhibitors may bind simultaneously (Fig. 3). Inspection of the reaction schemes (Fig. 2, 
3) shows that if two inhibitors have specific, independent sites on the enzyme, we will 
observe states where the enzyme indeed has two inhibitors bound (Fig. 3). These states 
cannot exist if both inhibitors bind to the same site (Fig. 2). Thus, if two inhibitors are able to 
bind simultaneously, we have a case of “mutually non-exclusive” binding. Here, presence of 
the second inhibitor will not only give an additive effect (increase of the number of 
inhibitory molecules), but will generate additional inhibited states of the enzyme. Therefore, 
on a molecular level we would expect a superadditive effect of two such inhibitors.  
It should be noted that the considerations above are made following some basic 
assumptions, namely that binding of an inhibitor will convert the enzyme to an inactive 
state, binding of substrate and inhibitor is reversible, and binding of any compound is fully 
independent from all other compounds. Thus, the equilibrium binding constant for inhibitor 
A is the same whether A binds to the unliganded enzyme, or to the enzyme that has 
substrate and/or another inhibitor bound. Given these assumptions, the mechanisms for 
activation (Fig. 4A), and non-competitive inhibition (Fig. 4B,C) show the different states in 
which an enzyme exists in the presence of two non-competitive inhibitors that bind to the 
same site (Fig. 4B), or to different sites of the enzyme (Fig. 4B). 
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Fig. 3. Reaction scheme for two mutually non-exclusive non-competitive inhibitors. Non-
competitive inhibition by two inhibitors (squares, triangles) binding to different sites on the 
target protein. Here, bindign of one inhibitor does not prevent binding of the other. Note 
that presence of the second inhibitor creates new inactive states of the target protein that are 
not possible if only one inhibitor is present. This applies even in the simplest theoretical 
case, where binding affinities of agonist and inhibitors are completely independent of each 
other. Thus, in the presence of two inhibitors of the same target protein that follow the rule 
of Bliss independence, i.e. mutually non-exclusive binding, synergy must be a necessary 
consequence. 
 
Fig. 4. Mechanism of catalysis and non-competitive inhibition of a Michaelis-Menten enzyme. 
(A) Mechanism for the activation of an enzyme following Michaelis-Menten kinetics. E = 
enzyme, S = substrate, P = product, KM = Michaelis constant, k2 = rate of product formation 
from ES. A simplified MM kinetic scheme is used, assuming no backward reaction EP  ES. 
(B) Inhibition of a Michaelis-Menten enzyme by two non-competitive inhibitors X and Y, 
which are mutually exclusive (e.g. binding to the same site). It is assumed that enzyme with 
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bound inhibitor is completely inactive, ie it does not form product. Either inhibitor X or Y can 
bind at any given time. Presence of the second inhibitor can only exert an additive effect but is 
not synergistic. (C) Inhibition of a Michaelis-Menten enzyme by two non-competitive 
inhibitors X and Y, which are mutually non-exclusive, i.e. binding to different sites on the 
enzyme. Here, both inhibitors may bind simultaneously, giving rise to synergistic inhibition. 
2.2 Michaelis-Menten enzymes 
In this section, a simple derivation of enzyme inhibition by one or two non-competitive 
inhibitors is given. To illustrate the consequences of mutually exclusive vs. non-exclusive 
binding, the simplest mechanisms are used. 
From the mechanism of a Michaelis-Menten-type enzyme (Fig. 4A) and the law of mass 
action, we find:  
 
  
 M
E S
K
ES
             
M
E S
ES
K
  (1)   
The enzyme E can only exist as free enzyme E, or enzyme-substrate-complex ES. The total 
enzyme concentration is [Etot], KM is the Michaelis constant. Only ES can form product, the 
maximum rate of product formation is Vmax. 
      totE E ES   (2) 
  max 2 totV k E  (3) 
V0, the actual rate of product formation at a given concentration of substrate depends on the 
fraction of ES that is present in the equilibrium. Thus V0 can be expressed in terms of 
“ocupancy”, or fES, the fraction of enzyme present in the enzyme-substrate complex ES. 
 
 
   ES
ES
f
E ES
   (4) 
  0 2V k ES      0 max tot
ES
V V
E
   ,      0 max max ES
ES
V V V f
E ES
   (5) 
Note that this equation converts readily to the common form of the Michaelis-Menten 
equation, if the definition of KM (equation 1) is substituted into equation 5. 
 0 max
1
1 M
V V
K
S


 (6) 
In the presence of a single non-competitive inhibitor, additional enzyme species are possible 
(EX, EXS in Fig. 4B). By definition of an inhibitor, these do not lead to any product 
formation. Then fES becomes 
 
 
       ,ES X
ES
f
E ES EX EXS
     (7) 
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The rate of product formation in presence of one non-competitive inhibitor is 
 0, max
1
1 1
X
M
X
V V
K X
S K
        
 (8) 
For two mutually exclusive inhibitors X and Y (Fig. 4B), one obtains: 
 0, , max
1
1 1
X Y
M
X Y
V V
K X Y
S K K
         
 (9) 
And for two mutually non-exclusive inhibitors (Fig. 4C), the rate equation is 
 0, , max
1
1 1 1
X Y
M
X Y
V V
K X Y
S K K
            
 (10) 
There is a simple technique to determine the type of enzyme inhibition by two inhibitors, 
and whether their action on the enzyme is synergistic. To this end, the ratio of the initial 
rates in the absence (control, V0), and in the presence of inhibitor (V0,X) is measured. S0 is the 
control signal, SX is the signal obtained in the presence of inhibitor. 
 
max
0 0
0,
max
1
1
1
1
1 1
M
X X X
M
X
V
K
S V XS
S V KV
K X
S K
                 
 (11) 
Thus, a straight-line curve is obtained when S0/SX is plotted against [X], the (varied) 
concentration of inhibitor X. The slope of this line (Fig. 6) gives the inhibition constant KX. 
This plot is linear over the entire range of inhibitor concentration. 
In the case of two mutually exclusive inhibitors, the ratio becomes 
 
 
max
0 0
, 0, ,
max
1
1
1
1
1 1
M
X Y X Y X Y
M
X Y
V
K
S V X YS
S V K KV
K X Y
S K K
                   
 (12) 
Presence of the second inhibitor only results in an additional term (Y/KY) that shifts the 
S0/SX,Y curve upwards. This term indicates additivity of the two inhibitors, but inhibitory 
potency (slope of the curve) is not altered. 
For two mutually non-exclusive inhibitors, the ratio is 
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max
0 0
, 0, ,
max
1
1
1 1
1
1 1 1
M
X Y X Y X Y
M
X Y
V
K
S V X YS
S V K KV
K X Y
S K K
                         
  (13) 
The difference between mutually exclusive and non-exclusive inhibitors can directly be seen 
from an experiment where the concentration of inhibitor X is held constant, and only [Y] is 
varied. Equation 13 can be rearranged to:  
 
0
,
1 1
X Y X Y X
S X Y X
S K K K
      
 (14) 
Compared to the case of mutually exclusive inhibitors, the curve of S0/SX,Y. Y is shifted 
upwards by a constant concentration of X, and the slope of the curve also increases by a 
factor of (1+X/KX).  
The ratio method shown here applies to the simplest case of synergistic action of drugs, two 
substances binding to the same target. It requires some basic kinetic data to be collected and 
gives a simple linear graph that can be quickly inspected for a qualitative result whether two 
substances act on the same or on different sites on an enzyme, and thus whether these two 
substances can be synergistic on their target or not. It should be noted that by taking the ratios, 
the control signal (uninhibited case, i.e. the largest signal) is divided by a signal that becomes 
progressively smaller and thus carries a higher error. It is needed to detect whether two curves 
have the same slope (mutually exclusive binding, additive effect), or different slopes (mutually 
non-exclusive binding, synergy). This difference has to be clearly demonstrated from 
experiment and data analysis, requiring data of sufficient quality to make this distinction. 
The technique provides two important pieces of information: 
1. The value of KX, the inhibition constant, is unchanged if two inhibitors are only 
additive, and is decreased (~ higher inhibitory potency) in the presence of the second 
inhibitor. Therefore, we have a clear, mechanism-derived definition of synergy on the 
molecular level. 
2. Conversely, the method allows to determine whether two inhibitors bind to the same, 
or to different sites on an enzyme. This may be an important result for drug 
development, and is obtained without need of structural data. (Note: strictly speaking, 
the result only tells whether binding of two inhibitors is mutually exclusive or non-
exclusive) 
The method has originally been presented for ligand-gated ion channels by Karpen and 
Hess (Karpen, Aoshima et al. 1982; Karpen and Hess 1986), and subsequently been used for 
the study of action of multiple inhibitors on ion channels (Karpen, Aoshima et al. 1982; 
Karpen and Hess 1986; Breitinger, Geetha et al. 2001; Raafat, Breitinger et al. 2010).  
The basic mechanism presented here is by far not sufficient to describe multimeric enzymes, 
enzynmes requiring cofactors, and various modes of inhibition. Enzymes may form 
multimers, binding of one inhibitor may affect binding of other others, and binding sites my 
overlap. More complex mechanisms of inhibition of Michaelis-Menten enzymes have been 
discussed, including those of several inhibitors acting on a single enzyme (Palatini 1983). 
Action of several inhibitors as well as antagonistic interaction of enzyme inhibitors have 
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been studied (Asante-Appiah and Chan 1996; Schenker and Baici 2009), and a major 
development in drug interaction analysis was the detailed mathematical treatment of 
enzyme kinetics and inhibition by Chou and Talalay (Chou 1976; Chou and Talalay 1977; 
Chou and Talalay 1981; Chou 2006; Chou 2010), covering the mechanistic Michaelis-Menten 
approach as well as logistic approaches.  
2.3 Ligand-gated ion channel receptors 
Ligand-gated ion channels are principal mediators of rapid synaptic transmission between 
nerve cells and in the neuromuscular junction. Compared to Michaelis-Menten type 
enzymes, their mechanism of activation is more complex, requiring an additional transition 
(Hess 1993; Colquhoun 1998). First step of ion channel activation is binding of the activating 
ligand (a neurotransmitter), which is governed by the principle of mass action (Hess 1993; 
Colquhoun 1998). Usually, more than one ligand molecule is required; depending on 
receptor type, models with two or three ligands binding prior to efficient channel opening 
have been discussed. Ligand binding induces an conformational change, where the receptor 
protein converts from the closed to an open ion-conducting state (Fig. 5A) (Hess 1993;  
Colquhoun 1998). Only the passing ions generate an electric signal and this signal can be 
recorded using patch-clamp techniques. Similar to the ES complex in enzymes, only the 
liganded receptor can undergo the opening transition. The mechanisms of non-competitive 
inhibition by two inhibitors binding to the same (Fig. 5B), or different (Fig. 5C) sites have 
been given. A similar derivation to the one for MM-enzymes can then be made.  
The signal in this case is not a rate of product formation, but an ionic current, namely the 
rate of ion translocation through the open channel. Assuming a constant transmembrane 
voltage, and only one conducting state (ie only one channel size, in reality several 
conductance levels have been observed for each ion channel receptor).  
The observed signal SL would then be: 
 L L Ch ionS I n J   (15) 
where IL is the observd current, nCh is the number of open channels, and Jion is the ion 
translocation rate. The maximum current signal would be observed if all ion channel were 
open at the same time. Fopen, the fraction of open channels, would then be equal to 1 (a 
theoretical value only). 
 max max openS I F  (16) 
Assuming that only receptors with two bound ligands can undergo the opening transition 
(Fig. 5A), we can define the fraction of open channels as  
 
 
       
2
2 2
( )
2 ( )
open
RL open
F
R RL RL RL open
      (17) 
Using the law of mass action, we can define 
 
  
 2D
R L
K
RL
  (18) 
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  
 2D
RL L
K
RL
  (19) 
 
 
 
2
2( )
RL
RL open
   (20) 
we can then obtain 
 0 max max 2
1
1 1
open
D
S I F I
K
L

 
    
 (21) 
 
 
Fig. 5. Mechanisms of activation and non-competitive inhibition of ion channel receptors  
(A) Minimum mechanism for the activation of a ligand-gated ion channel. Note that the 
channel-opening reaction comprises two elementary steps, ligand binding (dissociation 
constant KD) and conformational change to the open state (open-close equilibrium ). R = 
receptor, L = activating ligand. In this example binding of two ligand molecules is needed 
prior to channel opening. (B) Inhibition of an ion channel receptor by two non-competitive 
inhibitors X and Y, which are mutually exclusive (e.g. binding to the same site). Either 
inhibitor X or Y can bind at any given time. Presence of the second inhibitor can only exert 
an additive effect but is not synergistic. (C) Inhibition of an ion channel receptor by two non-
competitive inhibitors X and Y, which are mutually non-exclusive, targeting different sites 
on the receptor. Synergism is then observed as a necessary consequence of two mutually 
non-exclusive inhibitors. 

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In the presence of one non-competitive inhibitor X, we obtain the following equation for the 
signal SX:  
 max 2
1
1 1 1
X
D
X
S I
K X
L K

              
 (22) 
where KX is the inhibition constant, L is the concentration of activating ligand, and X the 
concentration of inhibitor. One can now readily compute the ratios of control current signal 
to signal in presence of inhibitor: 
 
max 2
0
max 2
1
1 1
1
1
1 1 1
D
X X
D
X
I
K
LS X
S KI
K X
L K


          
             
 (23) 
In case of two inhibitors binding to the same site (mutually exclusive), the ratio again 
becomes 
 0
,
1
X Y X Y
S X Y
S K K
    (24) 
For two non-exclusive inhibitors, targeting different sites on the recpetor, this ratio then is 
 0
,
1 1
X Y X Y X
S X Y X
S K K K
      
  (25) 
Equations 23 – 25 are identical to equations 11-14. 
Similar to the treatment of Michaelis-Menten enzymes, we obtain again a system of linear 
equations that describes the action of one or two inhibitors of ion channel receptors. If the 
concentration of inhibitor X is held constant, and the concentration of the second inhibitor, 
Y, is varied, the ratio S0 / SX,Y is shifted up by a constant amount X/KX but the slope (1/KY) 
is unchanged. The slope of the ratio curve represents the inhibitory potency, and the 
constant upward shift is due to the additive effect of two mutually exclusive inhibitors. 
In the presence of two mutually non-exclusive inhibitors, the slope (ie inhibitory potency) is 
increased by a factor of (1 + X/KX). Thus, if the mechanism underlying this analysis were 
followed, the “amount of synergy” could be calculated as 1 + X/KX. Often, quality of the 
data does not permit this quantitation, although the qualitative demonstration of synergy 
(increased inhibitory potency of drug A in the presence of drug B) is statistically safe. Thus, 
by taking the ratios of control and inhibited signals, we arrive at an equation that becomes 
mechanism-independent and corresponds to the principal equations used to describe drug 
interactions. The ratio method results in a simple graph that describes the type of joint 
action of two inhibitors on a common enzyme, neurotransmitter receptor, or general target 
protein (Fig. 6). 
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X + Y
mutually non-exclusive
X + Y
mutually exclusive
S
L
S
L,X,Y
Y alone
[Inhibitor Y]  
Fig. 6. Ratio method graph. Graph of signal ratio S0/SX,Y vs inhibitor concentration for the 
case of one inhibitor (black curve), two mutually exclusive inhibitors (gray curve), and two 
mutually non-exclusive inhibitors (light gray curve). In case of mutually non-exclusive 
binding the inhibitory potency of inhibitor Y is increased in the presence of inhibitor X, as 
indicated by the lower value of KY computed from the slope of the inhibition ratio curve. 
Note that the formalism described here becomes mechanism-independent and applies to 
Michaelis-Menten type enzymes as well as to more complex mechanisms of ion channel 
receptor inhibition. 
So far, a simple description of the action of two inhibitors on a common target has been 
derived. The mechanisms were based upon (i) a common binding site for two inhibitors, 
leading to mutually exclusive binding (Fig. 2), or (ii) two independent binding sites, leading to 
mutually non-exclusive binding (Fig. 3), Indeed, these simple models underlie (i) the principle 
of Loewe additivity (Loewe 1953; Berenbaum 1989), also referred to “similar”, or 
“homodynamic” action of drugs. Here, the expectation value for zero interaction is just 
additivity. Independent inhibitor sites (Fig. 3), in contrast, correspond to Bliss independence, 
“dissimilar”, “heterodynamic”, or “independent” action of drugs (Bliss 1939; Berenbaum 
1989). The combined effect of two such drugs will be more than additive, fulfilling the basic 
criterion of synergy. It has been recognized that these are the two limiting mechanisms for 
drug interaction (Bliss 1939; Finney 1942; Plackett and Hewlett 1948), and indeed both models 
are being used in the literature as zero interaction reference (Greco, Bravo et al. 1995).  
It is intuitive, and favoured by this author to view the concept of Loewe additivity as the 
zero interaction reference, and noting the superadditive response from Bliss independence 
as synergism. This definition is widely accepted (Segel 1975; Chou and Talalay 1977; 
Berenbaum 1989). Furthermore, it allows for a very intuitive definition of zero interaction, 
proposed by Loewe: if drug A and B are the same, B being a dilution of A. Naturally, action 
of “both” drugs would be similar, and thus we have a perfect model of additivity. 
www.intechopen.com
 
Toxicity and Drug Testing 
 
154 
However, what happens if we already know that drug A and B have completely different 
modes of action? Two drugs could be targeting different enzymes in a biochemical pathway. 
Of such a combination of drugs – having dissimilar action – we would expect superadditive 
behaviour. Can we call this synergy, or is it just expected from the mechanism and is now 
our zero reference? Arguments can be found for either view, and both models (and many 
more) are thus used and debated in the literature. 
Once we move to more complicated systems, mechanism-based analysis is no longer 
feasible, and more general descriptions of drug interaction are needed. However, they all 
relate to the basic models of additivity and independence that were described above. 
Equation 25 can be rearranged into the form 
 0
,
1
X Y X Y X Y
S X Y X Y
S K K K K
     (26) 
This equation is similar to a general equation that describes describing the joint action of 
two drugs on a specific target or biochemical process, presented by Greco et al. (Greco, 
Bravo et al. 1995). 
 1 2 1 2
,1 ,2 ,1 ,2
1 , , ,
X X X X
D D D D
f p
ID ID ID ID
       
 (27) 
Here, D1 and D2 are concentrations of drug 1 and 2 in a mixture; IDX,1 and IDX,2 are the 
concentrations that produce a certain effect (corresponding to EC50, or IC50 values);  is the 
synergism/antagonism parameter and p represents additional parameter(s) describing the 
“interaction” (joint action) of the two drugs. 
The models and derivations given above are indeed the simplest approach to synergism 
between drugs. At this time, we do not even have a complete description of the action of 
every drug. It has been pointed out that under physiological conditions, it is expected that 
indeed presence of a drug will always result in an altered state of metabolism and thereby 
affect other drugs (Gessner 1974). In many patients multiple drug regimes have to be given, 
and the metabolism of a critically ill person may differ from a healthy “control” volunteer. 
Taken together, medical reality is not sufficiently described by simplified models. However, 
as shown above, even from simple model cases we can understand mechanisms of synergy 
and can derive mechanism-independent formalisms to determine the type of joint action of 
drug combinations. 
In biomedical modelling, an alternative approach is the use of a mechanism-free description 
of activity, such as enzyme activity, ion channel function, the throughput of an entire 
biochemical pathway, or even cell survival in toxicity assays. The most common approach is 
the use of logistic equations that simply connect concentration of an effector (agonist or 
inhibitor) to the measured effect (enzyme activity, product formation, cell survival). The 
most comonly used formalism is that of the Hill equation. 
  0 max
50
1
1
n
E E
EC
L

    
 (28) 
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Here, E0 is the observed effect, Emax is the maximum signal, EC50 is the concentration of 
ligand L that produces 50 % of the maximum response, and n is a coefficient defining the 
steepness of the dose-response curve. The similarity to Michaelis-Menten type enzyme 
kinetics is obvious, yet the logistic formalism is not based on any mechanism. Indeed, 
complex clinical situations require use of mechanism-free models to analyze drug 
interactions (Chou 1976; Berenbaum 1978; Berenbaum 1980; Chou and Talalay 1981; 
Berenbaum 1989; Tallarida 1992; Greco, Bravo et al. 1995). 
In the following section some principles and formalisms for the analysis of drug synergism 
are briefly reviewed. An exhaustive review of all concepts is outside the scope of this text, 
readers are directed to several excellent, comprehensive reviews (Berenbaum 1989; Greco, 
Bravo et al. 1995; Tallarida 2001; Chou 2002; Toews and Bylund 2005; Chou 2006; Tallarida 
2006; Bijnsdorp, Giovannetti et al. 2011). 
3. Mechanisms and techniques of synergy testing in complex biomedical 
settings  
An example, modified from Berenbaum (Berenbaum 1989) is that of a woodcutter, able to 
cut 10 trees in a day. He is joined by a second woodcutter, also able to cut down 10 trees in a 
day. Together, they manage to cut 15 trees in one day. How do we describe this situation? 
One approach is that cutter A achieves 10 trees per day, our expectation value. Addition of 
cutter B results in 15 trees being cut, so there is synergy. Such an approach has been 
proposed e.g. by Gaddum, who only considered the effect of one agent and whether it was 
affected by another one being added (Gaddum 1940). This formalism is not used widely, as 
it obviously assigns synergism to the effects of several drugs too readily. 
Conversely, one would say that with two cutters, each able to cut 10 trees per day, the 
expectation value is 20 trees/day. If only 15 are achieved, they are antagonising each other. 
This is the application of additivity, and clearly, the combined effect is sub-additive, 20 trees 
would be just additive, and more than 20 would mean synergy. 
Mechanistically, one might argue that if cutter A works on a tree, then cutter B would not 
work on the same tree. Their action would be mutually exclusive, and the additive result 
would be expected. If, however, they are willing to work at the same tree together, they will 
be able to cut this tree in a much shorter time. In this case, they would be able to cut more 
than 20 trees in a day and their action would be mutually non-exclusive, leading to synergy. 
As stated above, pure mechanistic analysis is not sufficient (and not possible) for most 
clinical cases, so a general, mechanism-free analysis of drug interaction is needed. 
Berenbaum (Berenbaum 1989) has pointed out the similarity to non-parametric statistical 
tests that do not require information about the meaning of the values, or the distribution of 
populations from where the values originate. The equivalent in dose-response analysis is a 
logistic equation, that just describes a dose-response curve without any requirement of a 
mechanism. In such a setting, one would just define the desired outcome (enzyme 
inhibition, cell death, reduction of virus titer, ...), and then measure the effect achieved by 
varying doses of each drug alone, and in combination. 
The mechanisms shown above illustrate just the simplest mechanistic model. In real life, the 
situation is more complicated, as mechanisms of enzyme or receptor acitivity are more 
complex. Furthermore medical intervention is not only directed at single proteins, but at 
entire pathways or controlling structures, such as transcription factors, that initiate or 
control biochemical processes. Some therapies, such as cancer chemotherapy even aim at 
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cell destruction, i.e. they interfere with a complete living organism. In most of these 
situations, mechanisms of action are not known, or are too complex to work with. The 
additional problem is that with increasing complexity of the biological system, one finds an 
increasing paucity of experimental data. Even a simple dose-response curve, traditionally 
recorded with seven sensibly spaced concentration points, carries a significant error. By the 
rule of parsimony, one has to choose the simplest possible mechanism to describe 
experimental data. Thus, research is confronted with the dilemma of either 
oversimplification, or overinterpretation of results – a working compromise between these 
two extremes is needed. The pertinent models and methods have been extensively analyzed 
and reviewed in two excellent papers by Berenbaum (Berenbaum 1989), and Greco et al. 
(Greco, Bravo et al. 1995).  
Some of the main concepts are just briefly described: 
- Median effect analysis 
- Interaction index, isobole method and combination index 
- Response surface analysis 
3.1 Median effect analysis 
Chou et al. derived the median effect equation which follows from a detailed derivation of 
MM enzyme mechanisms (Chou 1976; Chou and Talalay 1977; Chou and Talalay 1981; Chou 
2006). 
 
1
d
d
Ed
M E
   (29) 
where d is the dose of a drug, Ed the effect caused by this amount of drug, M the median 
(dose causing 50 % effect, i.e. EC50 or IC50). Indeed, such an equation can be derived by 
rearrangement of the Michaelis-Menten equation (6): 
  
0
max
0
max
[ ]
1M
V
VS
VK
V


 (30) 
Here, [S] is the substrate concentration that gives the observed V0, KM is the Michaelis constant, 
and V0/Vmax is the effect caused by [S], expressed here as the fractional velocity. The median 
effect equation has been proposed as a central, unified equation from which the basic equation 
sets of Henderson-Hasselbalch, Scatchard, Hill, and Michaelis-Menten can be derived (Chou 
2006; Chou 2010). The median effect equation has been derived from MM-type enzymes from 
mathematical analysis. It can be extended to multiple-site systems in the form (Chou 2006) 
 
1
n
d
d
E d
E M
       (31) 
where n is the constant giving the slope of the dose-response curve. Note that n has often 
been equated with the number of binding sites, but this is an oversimplification that should 
be avoided since it is not valid in most cases. The value of n may be a measure of the degree 
of cooperativity between binding sites, but nothing more.  
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The equation can also be expressed in the form 
 
n
A
UA
f d
f M
      (32) 
where fA and fUA are the fractions of affected and unaffected enzyme, respectively. The 
importance of the median effect equation is that it is composed of ratios of effects (Ed, (1-Ed), 
or fA and fUA) and of the dose ratio (actual dose d, median dose M). Although derived from 
mechanistic analysis, the median effect equation cancels out mechanism-specific constants, 
and just links dose and effect in dimensionless ratios. This makes it a very versatile tool for 
the analysis of complex systems. The median effect equation can be linearized by taking 
logarithms on either side, giving the Hill plot (see Berenbaum 1989) which is a straight line 
for the plot of log(fA/fUA) vs. log d. 
  log log logA
UA
f
n d M
f
     
 (33) 
Thus the median effect equations can be seen as an extremely useful rearranged form of 
dose-response curves, linking ratios of drug doses to ratios of observed effects. The median 
equation will work with both, mechanism-based (eg Michaelis-Menten), and effect-based 
(eg logistic) equations, and provides a dimensionless measure for drug effects. The 
technique has been extensively tested and derived from mechanistic as well as purely 
mathematical considerations. The group of T.C. Chou have pioneered this field and 
developed software packages (CompuSyn ands CalcuSyn) that allow reliable testing of drug 
interaction parameters (Chou 2002; Chou 2006; Chou 2010). Well-founded in theory, the 
technique has found widespread use (Chou 2002; Chou 2006; Chou 2010; Bijnsdorp, 
Giovannetti et al. 2011), and the initital paper by Chou and Talalay (Chou and Talalay 1984) 
has been intensely cited and discussed.  
3.2 Interaction index, isobole method and combination index 
The interaction of two or more drugs to produce a combined effect can be described by the 
interaction index I (Berenbaum 1977). 
 1 2
,1 ,2X X
D D
I
ID ID
   (34) 
or written in terms of the median equations above 
 1 2
1 2
d d
I
M M
   (35) 
where, D1 , D2 d1 and d2 are concentrations of drug 1 and 2 that produce a certain effect if 
applied together; IDX,1 , IDX,2 , M1 and M2 are the concentrations that produce the same effect 
when given alone. For instance, if we want 50 % inhibition, then equation 34 would be: 
 1 2
50,1 50,2
D D
I
IC IC
   (36) 
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Here, IC50,1 and IC50,2 are the IC50 values of drug 1 and drug 2 alone. D1 and D2 are the doses of 
drug 1 and 2, respectively, that also produce 50 % inhibition when given together. The 
interaction index, proposed by Berenbaum (Berenbaum 1977), should be constant in case of 
zero interaction. The method has been extended by Berenbaum (Berenbaum 1985) and 
developed into a general method based on analysis of each drug alone and then simulating the 
combined action of both drugs based on Loewe additivity (see also Greco, Bravo et al. 1995).  
The interaction index underlies one of the most widely used graphical representations of 
drug synergism and antagonism, the isobologram. Isoboles were first used by Fraser in 1870 
(Fraser 1870; Fraser 1872) as simple, intuitive illustration without mathematical derivation. 
Here, the doses of drugs A and B give abscissa and ordinate, respectively, and the effect of 
drug combinations is plotted as graph (Fig. 7). In the example (Fig. 7), the effect plotted is 
for 50 % inhibition of an enzyme. The effects of each drug alone (i.e. IC50) can be read from 
the axes. The isobologram shows an effect, such as IC50 (IC10 or IC80, whatever effect is of 
interest) and which drug concentration is needed to achieve this effect.  
 
 
Fig. 7. Isobologram. Abscissa and ordinate units are the concentrations of drugs A and B. 
The solid black line connects concentrations that produce the same effect on the target 
protein, enzyme, or system. In this example, the IC50 line is given. In the simulation, drug A 
has an IC50 (concentration giving 50 % inhibition) of 500 a.u. (arbitrary units), IC50 of drug B 
is 100 a.u. From additivity (black line), the combination of 250 a.u. of A with 50 a.u. of B 
should also give 50 % inhibition (point A). If, 50 % inhibition are achieved at lower 
concentrations of the two drugs (e.g. 150 a.u. of A and 40 a.u. of B, point B1), the drugs 
would show synergism. If the observed inhibition by the combination was less than 50 %, 
drug A and B would interact in an antagonistic way (point C). Model lines of synergism 
(gray line) and antagonism (light gray line) are drawn. Note that in case of synergy between 
two drugs, the IC50 curve would not be a straight line but an upward concave (gray line), in 
case of antagonism a downward concave (light gray line). In practical application, one 
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would determine IC50 of one drug in the presence of a constant concentration of the other. 
IC50 would be found with the combination of 250 a.u. of A and 24 a.u. of B (point B2), or 110 
a.u. of A and 50 a.u. of B (point B3).  
Equations 34 – 36 define straight lines for two drugs that do not show any interaction 
(synergism or antagonism). Two drugs showing aditivity wold be expected to fall on the 
additivity line (Fig. 7). If the two drugs act synergistically, lower concentrations would be 
needed in the mixture to achieve the same effect. Their combination graph would be an 
upward concave (gray line in Fig. 7), following the unequality 
 1 2
,1 ,2
1
X X
D D
ID ID
   (37) 
Conversely, two antagonistic drugs would require higher doses in combination to achieve 
the same effect, and the resulting isobole would be an upward convex line (red line in Fig. 
7), of the general (un)equation 
 1 2
,1 ,2
1
X X
D D
ID ID
   (38) 
Representing a form of median effect equationry, isoboles have become a useful tool to 
present complex modes of drug interaction. An excellent review by Greco et al (Greco, 
Bravo et al. 1995) derives isoboles as 2-D sections through three-dimensional plots of drug 
action data. Depending on the shapes of the dose-response curves of both drugs, isoboles do 
not need to be linear (Greco, Bravo et al. 1995). Also, drug combinations may be biphasic, 
showing concentration ranges of synergy and ranges of antagonism (Berenbaum 1989). 
Equations 34 and 35 apply to the case of Loewe additivity, where the two drugs do not show 
synergy or antagonism. For drugs showing any type of interaction, equation 34 was 
extended to define a combination index (CI), indicating type and amount of interaction 
between two (or more) drugs with respect to the experimantal parameter being studied 
(Chou and Talalay 1983). 
 1 2
,1 ,2
 1 for antagonism
1  for additivity     
 1  for synergy     X X
D D
CI
ID ID

  

 (39) 
The CI can take values between 1 and infinity for antagonism, and runs between 0 and 1 for 
synergy. Chou and Chou (1988) have introduced the dose reduction index DRI (Chou and 
Chou 1988), which is based on the interpretation of the Combination index equation (39). 
Assuming that two drugs show synergy, one expects that a lower dose of each is needed to 
achieve the same effect. This lower concentration (D1 and D2 in equations 34-39) can be 
related to the median (IC50 in equation 36), to give the dose reduction index DRI. 
    1 2
1 1
CI
DRI DRI
   (40) 
Both, combination index CI and DRI can be used to plot drug combination data for 
visualization of synergy or antagonism (Fig. 8, see (Chou 2006)).  
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Fig. 8. Visualization of drug interaction data. (A) CI-fA plot: The combination index CI is 
plotted versus fA, the fraction of affected enzyme or biological function. (B) DRI plot: the 
dose reduction index DRI is plotted against fA. See text for definitions of terms. 
3.3 Response surface analysis 
Response surfaces can be calculated and are a way to represent effects of drug combinations 
as a contour plot where drug concentrations are plotted as a horizontal x-y- plane, and the 
effect is plotted on the z axis. Isoboles can be seen as 2D sections through response surfaces, 
and the method allows graphical analysis of drug interaction data, albeit at requirement of 
quite some mathematical and computational effort. From the dose-response data of each 
drug alone, the expected response surface based on the zero interaction reference of choice, 
is plotted. Then actual drug combination data are entered into the plot, and similar to 
isobole analysis, deviations from the reference surface indicate synergism or antagonism. 
The technique has been applied to synergism studies (Tallarida, Stone et al. 1999), and its 
general use reviewed and commented in great detail (Berenbaum 1989; Greco, Bravo et al. 
1995; Tallarida 2001). 
3.4 Practical limitations 
There is a need for a definition of synergy, antagonism, and the zero case (neither one nor 
the other). Sometimes, specific problems are discussed and authors feel compelled to use a 
unique treatment of the data. Pharmacologists, stasticians, clinicians, and representatives 
from other fields have different views and concepts. In various major reviews, 13 models to 
treat drug combination data have been proposed. The author would not encourage 
decisions as to right or wrong. Each model may be appropriate for a given situation, and not 
applicable to others. However, all models discussing synergy can be traced back to only two 
types of the “zero” (no interaction) case as discussed before 
- Loewe Additivity 
Both drugs exert an effect but are mutually exclusive, either one or the other can be 
active at a given time. This corresponds to a common site of interaction in the simplest 
mechanistic case (Fig. 2).  
- Bliss Independence 
Both drugs are mutually non-exclusive, both can be active at the same time. In the 
simplest case, each drug has a specific, independent interaction site (Fig. 3). 
A 
0,0 0,2 0,4 0,6 0,8 1,0
0,0
0,5
1,0
1,5
2,0
Synergy
Antagonism
Additivity
CI
f
A
B 
0,0 0,2 0,4 0,6 0,8 1,0
0
1
2
3
4
Synergy
Antagonism
Additivity
DRI
f
A
www.intechopen.com
 
Drug Synergy – Mechanisms and Methods of Analysis 
 
161 
Indeed all models refer to these two basic cases. Obviously, both have a different expecation 
of joint action of two drugs. Loewe additivity is best described by equation 34, and any 
deviation from this may be considered as synergy. In case of Bliss independencs, one would 
expect both drugs to act independently, and therefore the zero case already includes a more 
than additive effect of both drugs. The author sees two problems with this definition: (i) two 
purely additive drugs would have to be called antagonistic, including the sham combination 
of a drug with itself. (ii) If two mutually non-exclusive drugs already produce a 
superadditive effect, and we do not yet call this synergy, how do we define “true” synergy? 
In terms of isoboles, the baseline (no synergy, no antagonism) is already curved, in the ratio 
method (Fig. 6), the slope of the inhibition curve is increased already for the zero case, and 
one calculates a CI of less than one. Thus, to identify synergy, one has to select a gradual 
increase. It may be fairly easy to identify a deviation from a straight line (isobole), but for 
the CI a deviation from <1 to <<1 is expected. In the ration method, the steepness of th slope 
may be hard to compute, as the ratio SX/Scontrol is toe be calculated from small numerical 
values and thus carries a large error. 
Thus the definition of Loewe additivity is preferred by this author as the definition of no 
synergy. As shown in Fig.s 2 and 3, it can clearly be defined in mechanistic term. Dose-
response analysis also follows the definition. Addtivity correctly describes the purest 
control experiment, sham mixtures of the same drug, and it follows the general definition 
of synergy, where a combination produces more thant the sum of the individual 
components. 
It should be noted, however, that in many clinical applications, drug combinations are used 
that target two completely different target proteins, or pathways. In radiotherapy, the 
combination of radiation and drugs work together, and in combination lower doses of either 
are required compared to a single treatment. No baseline of Loewe additivity can be 
proposed for such a combination. Likewise, combinations of drugs that target completely 
different cellular pathways may work synergistically towards cell killing even though the 
two drugs are not mutually exclusive in their activity. Obviously, there is no single 
methodology that is appropriate for all biomedical situations. 
An additional problem in interpreting drug combination data is the quality of the measured 
data. Biological systems invariably carry experimental error, and thus borderline cases are 
almost impossible to assign. For example, a combination index is calculated to be 0.9 – is this 
a real deviation from unity (and thus synergy), or is it experimental error? 
Even with the best data, however, analysis of joint action of two drugs has another inherent 
problem. Two different drugs may have different dose-response characteristics. In this case, 
changes in effective concentrations may suggest synergy where there is none. A principal 
illustration of this problem is given in Fig. 9 (adapted from Chou (Chou 2006; Chou 2010)), 
showing that the same relative concentration change can produce quite different effects (Fig. 
9 A,B). Even for a single compound, there is a marked difference whether one investigates 
concentrations below or around EC50, or near saturation. Addition of the same drug in the 
concentration range around EC50 (ie the steepest part of the dose-response curve) gives rise 
to a strong increase in signal which may be misinterpreted as synergy. The shapes of 
isobolograms for drugs with different dose-response characteristics, and the complications 
resulting from this fact have been extensively studied (Berenbaum 1989; Greco, Bravo et al. 
1995; Tallarida 2001; Chou 2006). 
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Fig. 9. Dose-effect curves of different shape. Both curves were simulated using the Hill 
equation and the parameters Emax = 100 % , EC50 = 20 au (arbitrary units). (A) Curve 
simulated for n =1 (hyperbolic curve). (B) Simulated for n = 3 (sigmoidal curve). Note the 
difference in curve shape, and the different effect of a change of concentration of agonist A 
from 5 to 30 au. In the hyperbolic case, the effect increases 3-fold, in the sigmoidal case, the 
increase is 28.3-fold. Effects of changes in agonist concentration are different depending on 
the response range where they happen. Sigmoidal dose-response curves are steepest around 
the median (panel B). In the example, a 6-fold raise in concentration (from 5 to 30 au) will 
cause a 28.3-fold increase in the observed effect. Raising the concentration from 15 to 90 au, 
the effect only increases 3.2-fold. Thus, if presence of a second drug B increases 
cooperativity of drug A, or if drug B shifts the relevant dose-response range of A towards 
the median by purely additive (non-synergistic) means, one would observe a higher increase 
in effect than expected from addition and wrongly interpret this as synergy. 
4. Borderlines of synergism – Potentiation, coalism, inertism, metabolic 
interference 
From the simplest models presented here to advanced discussions, the situations of synergy 
could be traced back to the simple principles of additivity vs. independence. In all those 
cases, both drugs were having the same effect alone or in combination. The only difference 
was the magnitude of the effects. Synergism can also occur with combinations of drugs or 
methods that have completely different modes of action. In cancer therapy a combination of 
radiation and cytotostatica is often used. Combination of substances and environmental 
conditions (heat, pH, radiation) have indeed been analyzed for synergy (Johnson, Eyring et 
al. 1945). There are cases of one drug having no activity, but augmenting the activity of 
another, as observed for antinociception by acetaminophen in combination with 
phentolamine (Raffa, Stone et al. 2001). The extreme case would be the combination of two 
drugs that have no effect alone, but are effective in combination. On the othe hand, self-
synergy of paracetamol has been described by Tallarida et al., who showed that the drug 
binds to targets in different locations and thus facilitates its own activity (Raffa, Stone et al. 
2000). An interesting approach is an attempt to predict drug synergism from gene 
microarray data (Jin, Zhao et al. 2011). 
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Effect of drug 
combination 
Both drugs have 
same effect 
individually 
Only one drug is 
effective 
individually 
None of the two 
drugs has an effect 
individually 
Greater than zero 
reference 
Synergy, Synergism Synergism 
(potentiation) 
Coalism 
Equal to zero 
reference 
Additiviy / 
Independence 
Inertism Inertism 
Smaller than zero 
reference 
Antagonism Antagonism  
Table 1. The terminology of the combined action of drugs (after Greco, Bravo et al. 1995) 
Another effect leading to apparent synergy or antagonism is the effect some drug may have 
on uptake, metabolism and clearance of other drugs. Depending on the route of 
administration, metabolism by first liver pass must be considered, including one of the most 
critical steps of drug biotransformation, namely oxygenation (thus hydrophilization) by 
cytochrome P450, an oxygenase that catalyzes oxygenations of substrates using NADPH 
and oxygen (O2). This oxygenation R–H  R–OH is a crucial step in metabolism and 
eventual clearance of drugs and pharmaceuticals from the body. To date, 56 subtypes of 
cytochrome P450 are found in humans, some of which are critical in metabolism of 
endogenous substances such as medical drugs. Substances interfering with cytochrome P450 
may, therefore, have an impact on drug clearance and thus on the actual concentration of a 
certain drug in the body (Flockhart 1995; Flockhart and Oesterheld 2000; Shin, Park et al. 
2002; Takada, Arefayene et al. 2004). 
 
Resource Internet address Comment 
Drug interactions 
checker 
http://www.drugs.com/drug
_interactions.html  
Tool to query compounds that 
interact with a given drug 
Medscape drug 
interaction checker 
http://reference.medscape.co
m/drug-interactionchecker  
Tool to report on interactions 
between two drugs  
Cytochrome P450 drug 
interaction table 
http://medicine.iupui.edu/cli
npharm/ddis/  
List of drugs metabolized by cyt 
P450 isoforms (Flockhart 2007) 
Grapefruit juice/citrus 
fruit juice interactions 
http://www.mayoclinic.com/
health/food-and-
nutrition/AN00413  
Short list of drugs that interact with 
dietary citrus fruits 
Private resources http://www.environmentaldi
seases.com/article-drug-
interactions.html  
Website discussing case individual 
studies of interfering drugs 
Table 2. Internet tools for drug interactions in clinical settings 
There are numerous internet tools that list known drug interactions. A brief list of some 
such resources is given in table 2. Thus, some practical aspects have been covered, although 
synergisms and other interactions of drugs are not yet given enough weight in approval or 
recommendations of drug use. This is particularly relevant for the less well-defined field of 
herbal remedies. Their interaction with anticancer agents has been studied (Sparreboom, 
Cox et al. 2004), but our knowledge in this area is still far from comprehensive. 
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To date, the study of drug interaction in the biomedical field is widespread and must 
include the following aspects: 
- mechanism of action of a single drug 
- mechanisms of action of two (or more) drugs acting on the same physiological target 
- interaction of two drugs through side effects, secondary targets, etc 
- effects on metabolism of the primary drug 
- top-down observations of the performance of drug combinations in patients 
Going down this list it becomes clear that pure mechanistic studies – although essential – are 
not sufficient to cover all aspects of drug interaction. Clinical observation is the – equally 
essential – other end of the spectrum and the gap between these two positions is indeed 
narrowing.  
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